Pipeline
We have been cultivating a pipeline of novel, oral drug candidates to help stop the current coronavirus pandemic (COVID-19) and prevent the next.
INFORMATION ON POMOTRELVIR (PBI-0451)
Pomotrelvir, an investigational Coronavirus Main Protease (Mpro) Inhibitor
Existing COVID-19 treatment options are falling short due to safety concerns, lack of efficacy against new variants, significant drug-drug interactions (DDIs), limited access, and other factors. In non-clinical studies our lead product candidate, pomotrelvir, has demonstrated potent antiviral activity against multiple human coronaviruses such as MERS, SARS, OC43 and 229E as well as recent SARS-CoV-2 variants of concern, including those in the Omicron lineage. Data from both non-clinical and Phase 1 clinical trials support pomotrelvir as a well-tolerated, stand-alone, ritonavir-free oral regimen. In December 2022, we completed enrollment in a Phase 2 clinical trial to evaluate the antiviral activity, safety and efficacy of pomotrelvir, enrolling 242 test-positive patients across multiple sites in the United States. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering. Contact us here.
Blocking Replication Before It Begins
Over the last 40 years, significant progress has been made in our understanding of how viruses infect cells, replicate, and spread within the body. We believe a promising method for treating and preventing coronavirus infections is to target the coronavirus Main Protease (Mpro), a highly-conserved protein required for the earliest stages of coronavirus replication. Blocking this target blocks the virus’ ability to replicate. We believe the highly conserved nature of Mpro across multiple coronaviruses, including SARS, MERS, and emerging SARS-CoV-2 variants of concern, supports the potential of this target for both known and potential future coronavirus strains and variants. These insights led to the design of pomotrelvir, a coronavirus Mpro inhibitor with demonstrated in vitro activity against multiple strains of coronaviruses. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering. Contact us here.